Key Points Revenue increased 51% year over year to $309.9 million for Q2 FY2026. Non-GAAP earnings per share improved to $(0.03) from $(0.40) in the prior year, far ahead of management's outlook.

As Neka Kayda, the world's first cloned red wolf, celebrates her first birthday, Colossal Biosciences reflects on the ...